Vaccine Technologies

Vaccine Technologies, Inc. (VTI) is a biotechnology company dedicated to the discovery and development of novel vaccine platforms for the treatment and prevention of infectious diseases, with a primary focus on HIV and Hepatitis B. The company utilizes its proprietary LFn-fusion protein platform, which employs a detoxified anthrax-derived polypeptide to facilitate the intracellular delivery of antigens, thereby inducing potent cellular and humoral immune responses. VTI's lead program, LFn-p24C, is a therapeutic HIV vaccine that has demonstrated safety and immunogenicity in Phase 1 clinical trials. Headquartered in Boston with a significant GMP manufacturing and R&D presence in Haikou, China, VTI is positioned to address global health challenges through scalable and innovative immunization solutions.